Delivery Order SPE2DB22D1017-SPE2DB25FE9UK

Award Date 11/22/24
Potential Completion Date 11/25/24
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,147.52 firm fixed-price delivery order contract is for the supply of XCOPRI 50 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 13, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,709.34 firm fixed-price contract is for the delivery of XCOPRI 100 MG TABLET 30S, a pharmaceutical product, through November 2024. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $1,768.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medical product XCOPRI 150 MG TABLET 30S, with a firm fixed-price pricing type and an ultimate completion date of December 20, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,624.02 firm fixed price contract is for the delivery of the drug XCOPRI 150 MG TABLET 30S, with a completion date of May 4, 2023. This award is not associated with a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,110.92 firm fixed-price delivery order is for the supply of the medication XCOPRI 150 MG TABLET 30S and has a completion date of January 31, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,141.05, is a delivery order for the pharmaceutical product XCOPRI 200 mg tablet. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $1,166.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XCOPRI 100 MG TABLET 30S, a pharmaceutical product, with an ultimate completion date of November 6, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,323.01 firm fixed-price delivery order is for the supply of XCOPRI 50-100 MG TITRATION PAK medication. The contract has an ultimate completion date of February 26, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to the Amerisourcebergen Drug Corp Corporate Office Division, a major pharmaceutical distribution company. The $2,415.19 Firm Fixed Price Delivery Order is for the supply of XCOPRI 100 MG TABLET 30S, a prescription medication. The contract does not have a set-aside designation and has a period of performance through June 27, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,768.44 firm fixed-price delivery order contract is for the supply of XCOPRI 200 MG TABLET 30S, a pharmaceutical product. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FE9UK
    Delivery Order

This is a $1,802.37 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of XCOPRI 200 MG TABLET 30S, a medical product, with a completion date of November 25, 2024. This award is not designated as a set-aside contract.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 2/21/25, 9:39 AM